49 results about "Haemostatic agent" patented technology

Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches, orthopedic pins (including bone filling augmentation material), adhesion barriers, stents, guided tissue repair / regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, atrial septal defect repair devices, pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, wound dressings, and hemostats. The polyhydroxyalkanoates can contain additives, be formed of mixtures of monomers or include pendant groups or modifications in their backbones, or can be chemically modified, all to alter the degradation rates. The polyhydroxyalkanoate compositions also provide favorable mechanical properties, biocompatibility, and degradation times within desirable time frames under physiological conditions.

The present invention is directed to a hemostatic wound dressing that utilizes a fibrous, fabric substrate made from carboxylic-oxidized cellulose and containing a first surface and a second surface opposing the first surface, the fabric having flexibility, strength and porosity effective for use as a hemostat; and further having a porous, polymeric matrix substantially homogeneously distributed on the first and second surfaces and through the fabric, the porous, polymeric matrix being made of a biocompatible, water-soluble or water-swellable cellulose polymer, wherein prior to distribution of the polymeric matrix on and through the fabric, the fabric contains about 3 percent by weight or more of water-soluble oligosaccharides.

The invention relates to a modified starch material for biocompatible hemostasis, biocompatible anti-adhesion, tissue healing promotion, absorbable surgery sealing and tissue adhesion. The invention applies biocompatible modified starch to animal tissues, wherein the modified starch material has the molecular weight of more than 15,000 daltons, and the particle diameter of between 1 and 1,000 mu m. The modified starch hemostatic material has stypticity, reduces hemorrhage, blood oozing and tissue fluid oozing of wounds, maintains relative moistening or drying of wound surfaces or the wounds, inhibits bacterium growth and inflammation reaction, and contributes to locally diminish inflammation of the wounds and relieve pain of patients. Moreover, the modified starch material can wash local parts after operation is over and remove redundant modified starch which does not participate in hemostasis, and can easily remove haemostatic under the condition of debridement treatment after self-help and first-aid treatment of war wounds; and hemostatic materials with a small amount of modified starch can be absorbed by the body, so that the pain of tearing of gauzes and bandages on people is avoided.

Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with / without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.

A device for promoting the clotting of blood in body cavities includes a flexible body portion; an expandable member located on the flexible body portion; and a blood clotting material attached to the expandable member. When used, insertion of at least a portion of the blood clotting material into the body cavity causes at least a portion of the blood clotting material to contact blood emanating from a bleed site. Methods of providing therapies to tube-shaped organs include the steps of providing suitable devices having expansion capabilities, positioning the devices at the appropriate bleed sites, and expanding the devices to cause blood clotting materials to contact the bleed sites. Materials that may be used as the blood clotting material include zeolites, molecular sieve materials, diatomaceous earth, clay, silica-based materials, oxidized cellulose, carboxymethyl cellulose, bioactive glass, biological hemostats, chitosan, and combinations of the foregoing.

A gingival retraction material and method of fabrication. The material comprises a carrying medium, retraction medium, and an anti-evaporation component. Preferably the carrying and retraction media are a clay such as kaolin, and the anti-evaporation component is glycerin. Additional components may be added to the material such as aluminum chloride, aluminum sulfate, ferric chloride, ferric subsulfate, styptics, haemostatic agents, coagulants coloring and flavoring. The material may be packaged in a kit with components to apply the material. Further disclosed is the method for making the material. Also disclosed is a delivery system for medication that includes a carrying medium, anti-evaporation component and a medication.

A haemostatic kit to be used as a medical device provides for a containment unit and a haemostatic agent in said containment unit, said haemostatic agent occupying less than 90% of the volume of the containment unit. This allows for facile and consequently sterile preparation of, for instance, a gelatin paste for use in haemostatis when combined with saline, thrombin or another agent to assist in haemostatis.

The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field.

A hydrogel tissue adhesive having increased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm amine in the presence of a polyol additive, which retards the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, including but not limited to, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; as a plug to seal a fistula or the punctum; adhesion prevention to prevent undesired tissue to tissue adhesions resulting from trauma or surgery; and as a hemostat sealant.

The invention discloses a powder absorbable haemostat and its preparation method, which belongs to the technical field of novel hemostatic material. The main components are chitosan, sodium alginate and hyaluronic acid. The weight ratio of chitosan to sodium alginate to hyaluronic acid is (0.1-10): (0.1-10): 1, The mass fraction of a cross-linking agent calcium chloride solution is 0.5-5 wt%. The invention also discloses a preparation method of the powder absorbable haemostat. According to the invention, the soybean oil is taken as an oil phase, calcium chloride is taken as a cross-linking agent, composite microspheres of chitosan, sodium alginate and hyaluronic acid can be obtained through a simple emulsification crosslinking process, the composite microspheres is dried to obtain the powder absorbable haemostat. According to the invention, the performance advantages of chitosan, sodium alginate and hyaluronic acid are combined by the product, so that the product has a plurality of haemostasis mechanisms which can rapidly suck water and swell, and the powder absorbable haemostat has the good anti-adhesion performance and characteristic of promoting the heal of the wound.

The invention relates to an external natural zeolite emergency survival haemostatic which adopts a natural zeolite haemostatic or a modified natural zeolite haemostatic directly; the raw materials of the natural zeolite comprises the following components: silicon oxide, aluminum oxide, titanium oxide, ferric oxide, magnesium oxide, calcium oxide, sodium oxide and potassium oxide; wherein, the total content of the silicon oxide and the aluminum oxide is more than 70 percent; the aperture of the natural zeolite is 0.3 to 0.2nm, the specific surface area is 30 to 1,000m<2> / g and the pore volume is 0.2 to 1.0cm<3> / g, and the diameter of particles of the natural zeolite haemostatic is 1mum to 1mm. The preparation method is simple and the hemostatic effect is good, thus being used for hemostasis in different medical situations.

The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and / or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.

The invention relates to a rapid haemostat using mipor starch with a high specific surface area as a main raw material and a preparation process thereof. The rapid haemostat capable of being absorbed by a human body is prepared by using the mipor starch with the high specific surface area as the raw material and adding growth factors stimulating the rapid healing of a wound and an antimicrobial with diminish inflammation and infection-resistant effects. The haemostat not only can more rapidly and effectively arrest bleeding, but also can effectively accelerate the healing, the diminish inflammation and the infection resistance of the wound.

The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the haemostatic agents. Preferred compositions utilize Poly(N-vinylpyrrolidone), Poly(2-ethyl-2-oxazoline) as thickening agents and ferric sulfate as an active ingredient.

The present invention provides a preparation method of an external-use ophicalcitum compound emergency hemostat. The present invention grinds the natural ophicalcitum into a certain particle diameter, carries out the calcium chloride modification treatment through different temperature treatments, and obtains the ophicalcitum compound material with high hematopoietic function by mixing with other auxiliary compound materials. The present invention can be used for hemostasis on different medical occasions, can be combined with other medical materials and medical apparatuses, can be made into adhesive bandage, transfusion bandage, self-adhesive dressing, tablet and capsule core material, operation packet, first-aid packet, etc., and can also be made as the oral medicine and be used with other external-use medicines so as to get better curing effect. The present invention has the advantages of simple and feasible operation, abundant materials, low price and easy access, convenient application, good hematopoietic effect and less discharged heat.

Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

The invention relates to the technical field of hemostatics, and particularly provides an injectable hydrogel hemostatic based on marine-derived gelatin as well as application and application method of the hemostatic. According to the weight percentage of 100%, the injectable hydrogel hemostatic based on the marine-derived gelatin is prepared from the following components in percentage by weight:0.1%-10% of chemically-modified marine-derived gelatin, 10%-20% of a photo-crosslinking gelator, 0.1%-15% of a tissue adhesion factor, 0.1%-0.5% of a photoinitiator, and a dissolved amount of solvent.The injectable hydrogel hemostatic disclosed by the invention has a rapid and good hemostatic effect, has no extra trauma to surrounding tissues in a hemostatic process, has a degradable characteristic, and can be widely applied to hemostasis of human or animal tissues, visceral accidental wounds or surgical wounds.

Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.

A haemostatic agent delivery device (100) comprising an external tube (101) having a handle (102) mounted at its proximal end and an opening (104) located at its distal end for delivering a haemostatic agent over and sucking blood at a haemorrhagic site simultaneously; and an internal tube (109) having an absorbent (105) across its distal end, a controller (106) and at least one connecting means (107) at its proximal end for loading of haemostatic agent or channeling of sucking force under the trigger of the controller (106); wherein in use the internal tube (109) is introduced into the external tube (101) and pushed along the external tube (101) distally to cause the suction of blood through the absorbent (105) while simultaneously causes compression of the haemostatic agent over the haemorrhagic site.

The invention relates to a polyurethane adhesive containing catechol groups as well as a preparation method and application of the polyurethane adhesive. The invention provides a bonding system which is prepared from the following components in percentage by mass: 60 to 65 percent of isocyanato-terminated polyurethane prepolymer, 10 to 18 percent of micromolecular polyamine containing catechol groups and the balance of solvent. The invention also provides an adhesive with excellent bonding capacity and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing the components of the adhesive system, and standing to react for several seconds. The adhesive disclosed by the invention has excellent adhesion capacity on various materials such as biological tissues, metals and ceramics in a dry environment and underwater, and has a wide application prospect. Meanwhile, the adhesive disclosed by the invention is good in biocompatibility, can promote endogenous blood coagulation, and has the potential of serving as a medical hemostatic and a tissue adhesive.

The invention provides a multifunctional skin lotion for painless injection and trauma clearance, which comprises (by weight ratio) disinfectant 0.001-10 parts, analgesic agent 0.001-10 parts, antiinflammatory agent 0.001-10 parts, haemostatic agent 0.001-10 parts, and dissolvent 20-99.996 parts.

The invention provides a dental device comprising a sheath for fitting over a tooth, the sheath carrying a haemostatic agent in at least one region thereof, wherein the sheath comprises a generally cylindrical body having at least a first end and a second end, at least one of said first and second ends presenting a circumferential margin carrying at least part of the haemostatic agent, and wherein the at least one end carrying at least part of the haemostatic agent is open to a cavity and the other end is closed. A method of inhibiting or preventing gingival bleeding and a method of retracting gingivae using such a device are also provided.

The invention discloses a rapid hemostatic product for clinical operation wounds, as well as a preparation method and application of the rapid hemostatic product. The rapid hemostatic product comprises a matrix containing a microbial transglutaminase (mT6), wherein the amino acid sequence of the transglutaminase is the protein sequence coded by the gene shown in SEQ ID NO.: 3, or the protein sequence shown in SEQ ID NO.: 4. Specifically, the rapid hemostatic product is selected from a hemostatic, a hemostatic device, a hemostatic first-aid kit or a common hemostatic product; the matrix adopts a fluid or semisolid form, which can be absorbed by a human body, or a plastic gel or colloid form. The rapid hemostatic product contains the microbial transglutaminase and gelatin. The rapid hemostatic product has the advantages of rapid hemostatic property, convenience for use, prevention on organ adhesion, promotion on wound healing, low toxic and side effects, complete absorption and the like. The rapid hemostatic product can be used as a medical hemostatic material or product for clinical operation wounds, can stop bleeding rapidly, prevents organ adhesion, is easy to absorb, has little possibility of spreading diseases, and is low in cost.

Provided is a tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

The invention relates to the field of biomedical materials, in particular to ultralow-concentration single-component polypeptide hydrogel as well as a preparation method and application thereof. Carboxylated polypeptide used as a polymer skeleton is modified in one step to obtain catechol functionalized polypeptide, and then chemical bond-hydrogen bond co-crosslinked single-component polypeptide hydrogel is obtained through oxidation and freezing physical treatment. The ultralow-concentration single-component polypeptide hydrogel not only has ultralow critical gelling concentration and heat-resistant, salt-resistant and urea-resistant stability, but also has tissue interface clearing performance. The ultralow-concentration single-component polypeptide hydrogel has excellent biocompatibility and biodegradability, and can quickly and efficiently stop bleeding and promote wound healing. The single-component polypeptide hydrogel disclosed by the invention is simple in preparation method, low in cost and convenient to use, and has an important clinical application potential in the aspects of wound haemostat, sealant and wound auxiliary materials.

A microstructured hemostat comprising multiple layers of microstructure, each layer characterized by one or more length scales, is described. Microstructured hemostats of the present invention, can reduce the time for blood coagulation, control the morphology of the coagulation, and provide a novel diagnostic platform for evaluation of coagulation function from a morphological perspective.